0001415889-17-001295.txt : 20170802
0001415889-17-001295.hdr.sgml : 20170802
20170802060021
ACCESSION NUMBER: 0001415889-17-001295
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170519
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAFFUID PAUL W
CENTRAL INDEX KEY: 0001170363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37861
FILM NUMBER: 17998196
MAIL ADDRESS:
STREET 1: MABVAX THERAPEUTICS HOLDINGS, INC.
STREET 2: 11588 SORRENTO VALLEY ROAD, SUITE 20
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MABVAX THERAPEUTICS HOLDINGS, INC.
CENTRAL INDEX KEY: 0001109196
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930987903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11535 SORRENTO VALLEY ROAD
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8582599405
MAIL ADDRESS:
STREET 1: 11535 SORRENTO VALLEY ROAD
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: TELIK INC
DATE OF NAME CHANGE: 20000313
4
1
form4-08022017_030809.xml
X0306
4
2017-05-19
0001109196
MABVAX THERAPEUTICS HOLDINGS, INC.
MBVX
0001170363
MAFFUID PAUL W
C/O MABVAX THERAPEUTICS HOLDINGS, INC.
11535 SORRENTO VALLEY RD., SUITE 400
SAN DIEGO
CA
92121
false
true
false
false
EXECUTIVE VICE PRESIDENT
Common Stock
2017-05-19
4
P
0
2857
1.75
A
24083
D
Common Stock
2017-05-19
4
P
0
3228
A
27311
D
Class A Warrant
5.55
2017-05-19
4
S
0
2079
D
Common Stock
2079
0
D
Class B Warrant
6.29
2017-05-19
4
S
0
2079
D
Common Stock
2079
0
D
These shares were received in exchange for making an investment under the terms of the Company's May 2017 public offering equal to 50% of investment made in the Company's August 2016 public offering, and for the cancellation of (i) warrants to purchase 2,079 shares of the Company's common stock at a price per share of $5.55 issued to the Reporting Person on August 17, 2016 and (ii) warrants to purchase 2,079 shares of the Company's common stock at a price per share of $6.29 issued to the Reporting Person on August 17, 2016.
Warrant is immediately exercisable and expires on August 17, 2019.
These warrants were cancelled and exchanged for the right to receive 3,228 shares of common stock of the Company.
/s/ Jeremy D. Glaser , Attorney-in-Fact
2017-08-02